Clinical applications of hormonal therapy in ovarian cancer

Current Treatment Options in Oncology

Volumn 6, Issue 2, 2005, Pages 97-102

  Rao, Gautam G ^b   Miller, David S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; DOFETILIDE; ESTROGEN RECEPTOR; HORMONE DERIVATIVE; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PAROXETINE; PLATINUM DERIVATIVE; TAMOXIFEN;

ACNE VULGARIS; ALOPECIA; APPETITE DISORDER; ARTHRALGIA; ASTHENIA; BODY WEIGHT DISORDER; BONE PAIN; BREAKTHROUGH BLEEDING; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CARPAL TUNNEL SYNDROME; CATARACT; CHLOASMA; CLINICAL TRIAL; CONFUSION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRY SKIN; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GALACTORRHEA; GALLBLADDER DISEASE; GLUCOSE INTOLERANCE; HEADACHE; HEART FAILURE; HEPATITIS; HIRSUTISM; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; INCREASED APPETITE; INJECTION SITE REACTION; INSOMNIA; KERATOPATHY; LETHARGY; LUNG EMBOLISM; MALAISE; MASTALGIA; MELANOMA; MENSTRUAL IRREGULARITY; MENTAL INSTABILITY; METRORRHAGIA; MOOD DISORDER; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OPTIC NERVE DISEASE; OSTEOPOROSIS; OUTPATIENT; OVARY CANCER; PRURITUS; RETINOPATHY; REVIEW; SWEAT GLAND DISEASE; THROMBOPHLEBITIS; THROMBOSIS; VAGINA DISCHARGE; VAGINITIS; VASOMOTOR DISORDER; VISUAL DISORDER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 15344343626     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0017-y     Document Type: Review

References (45)

1. Koonings PP, Campbell K, Mishell DR, et al.: Relative frequency of primary ovarian neoplasms: A 10-year review. Obstet Gynecol 1989, 74:921-926.
2. American Cancer Society: Cancer facts and figures: 2004 Atlanta, GA: ACS; 2004
3. Surveillance, Epidemiology, and End Results Program (SEER). Accessible online at http://www.seer.cancer.gov/. Accessed December 2, 2004.
4. Young RC, Chabner BA, Hubbard SP, et al.: Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978, 299: 261-1266.
5. Lee BH, Hecht JL, Pinkus JL, et al.: WT1, estrogen receptor, and progesterone receptor as markers for breast and ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002, 117:745-750.
6. Lazo JS, Schwartz PE, MacLusky NJ, et al.: Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro. Cancer Res 1984, 44:2266-2271.
7. Miller DS, Teng NH, Ballon S: Epithelial ovarian carcinoma in patients with intersex disorders: The role of pituitary gonadotropins in ovarian tumorigenesis. Gynecol Oncol 1986, 24:299-308.
8. Mizejewski GJ, Beierwaltes WH, Quinones J: Uptake of radioiodinated human chorionic gonadotropin in ovarian carcinoma. J Nucl Med 1971, 13:101.
9. Kammerman S, Demopoulos RI, Raphael C, et al.: Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 1981, 12:886-890.
10. Al-Timimi A, Buckley CH, Fox H: An immunohistochemical study of the incidence and significance of human gonadotropin and prolactin binding sites in normal and neoplastic human ovarian tissue. Br J Cancer 1986, 53:321-329.
11. Graves PE, Surwit EA, Davis JR, et al.: Adenylate cyclase in human ovarian cancers: sensitivity to gonadotropins and Non-hormonal activators. Am J Obstet Gynecol 1985, 153: 77-882.
12. Nakano R, Vitayama S, Yamoto M, et al.: Localization of gonadotropin binding sites in human ovarian neoplasms. Am J Obstet Gynecol 1989, 161:905-910.
13. Simon WE, Albrecht M, Hansel M, et al.: Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Instit 1983, 70: 39-845.
14. Gwinn ML, Lee NC, Rhodes PH, et al.: Pregnancy, breast feeding, and oral contraceptives, and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990, 43:559-568.
15. Schildkraut JM, Calingaert B, Marchbanks PA, et al.: Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Instit 2002, 94:32-38.
16. Cunat S, Hoffmann P, Pujol P: Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004, 94:25-32.
17. Anderson GL, Judd HL, Kaunitz AM et al.: Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative Randomized Trial. JAMA 2003, 290:1739-1748.
18. Markman M, Webster K, Zanotti K, et al.: Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 2004, 93:390-393.
19. Williams CJ, Simera I. Tarnoxifen for relapse of ovarian cancer. The Cochrane Database of Systematic Reviews 2004, 3.
20. Perez-Gracia JL, Carrasco EM: Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research. Gynecol Oncol 2002, 84:201-209.
21. Markman M, Iseminger KA, Hatch KD, et al.: Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 1996, 62:4-6.
22. Hatch KD, Beecham JB, Blessing JA, et al.: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68:269-271.
23. Trope C, Marth C, Kaern J: Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000, 36:59-67.
24. Van der Velden J, Gitsch G, Wain GV, et al.: Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995, 5:301-305.
25. Cutuli B, Petit JC, Fricker JP, et al.: Thromboembolic accidents in postmenopausal patients with adjuvant treatment by tamoxifen; frequency, risk factors, and prevention possibilities. Bull Cancer 1995, 82:51-56.
26. Physician's Drug Reference, 2004. Montvale, NJ: Medical Economics Co., 2004.
27. Stearns V, Johnson MD, Rae JM, et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
28. Dowsett M, Haynes BP: Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 2003, 86:255-263.
29. Wilailak S, Linasmita V, Srisupundit S: Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anticancer Drugs 2001, 12:719-724.
30. Wiernik PH, Greenwald ES, Ball H, et al.: High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Easter Cooperative Oncology Group Study PD884. Amer J Clin Oncol 1998, 21:565-567.
31. Veenhof CHN, van der Burg MEL, Nooy M, et al.: Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur J Cancer 1994, 30A:697-698.
32. Sikic BI, Scudder SA, Ballon SC, et al.: High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group. Semin Oncol 1986, 13: 6-32.
33. Malinovsky KM, Cameron D, Douglas S, et al.: Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast 2004, 13:363-368.
34. Malfetano J, Beecham JB, Bundy BN, et al.: A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. Am J Clin Oncol 1993, 16:149-151.
35. Malik STA, Slevin ML: Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary - a new therapeutic approach? Br J Cancer 1991, 63:410-411.
36. van der Vange N, Greggi S, Burger CW, et al.: Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncologica 1995, 34:813-820.
37. Kaunitz AM: Injectable long-acting contraceptives. Clin Obstet Gynecol 2001, 44:73-91.
38. Paskeviciute L, Roed H, Engelholm SA: No rules without exception: Long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol 2002, 86:297-301.
39. du Bois A, Meier W, Luck HL et al.: Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomized trial of the German Arbeitsgerneinschaft Gynaekologishe Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 2002, 13:251-257.
40. Miller DS, Brady MF, Barrett RJ: A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 1992, 15:125-128.
41. Sugimoto AK, Hodsman AB, Nisker JA. Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertil Steril 1993, 60:672-674.
42. Fishman A, Kudelka AP, Tresukosol D, et al.: Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med 1996, 41:393-396.
43. del Carmen MG, Fuller AF, Matulonis U, et al.: Phase II trial of anastrozole in women with asymptomnatic müllerian cancer. Gynecol Oncol 2003, 91:596-602.
44. Papadimitriou CA, Markaki S, Siapkaras J, et al.: Hormonal Therapy with letrozole for relapsed epithelial ovarian cancer. Oncol 2004, 66:112-117.
45. Bowman A, Gabra H, Langdon SP, et al.: CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002, 8: 233-2239.